<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01609478</url>
  </required_header>
  <id_info>
    <org_study_id>CQMF149E2203</org_study_id>
    <secondary_id>2012-000520-18</secondary_id>
    <nct_id>NCT01609478</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, 12-week Treatment, Parallel-group Study to Assess the Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate (75 and 150 µg o.d.) in Patients With Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To provide the efficacy, safety and pharmacokinetics of indacaterol acetate in patients with
      persistent asthma to support dose selection of indacaterol in fixed dose combination QMF149.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume in One Second (FEV1) After 12 Weeks (Day 85)</measure>
    <time_frame>after 12 weeks (Day 85)</time_frame>
    <description>Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose after 12 weeks (Day 85)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire 5 (ACQ-5) After 12 Weeks (Day 85)</measure>
    <time_frame>aftert 12 weeks (Day 85)</time_frame>
    <description>The Asthma Control Questionnaire (ACQ-5) is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze. The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). A negative change in score indicates improvement in symptoms. MIXED model: Change from baseline in ACQ-5 = treatment + gender + baseline ACQ-5 score + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Expiratory Volume in One Second (FEV1) After 2 Weeks (Day 15), 4 Weeks (Day 29), and 8 Weeks (Day 57) of Treatment.</measure>
    <time_frame>Day 15, Day 29 and Day 57</time_frame>
    <description>Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose after 2 weeks (Day 15), 4 weeks (Day 29), and 8 weeks (Day 57) of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 at All Time Points</measure>
    <time_frame>Day 1, Day 2, Day 14, Day 15, Day 84, Day 85</time_frame>
    <description>Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards. FVC is measured on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 at all time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1)/ Forced Vital Capacity (FVC) on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85</measure>
    <time_frame>Day 1, Day 2, Day 14, Day 15, Day 84, Day 85</time_frame>
    <description>Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Flow (FEF 25-75% )on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85</measure>
    <time_frame>Day 1, Day 2, Day 14, Day 15, Day 84, Day 85</time_frame>
    <description>Forced Expiratory Flow (FEF 25-75%) was measured via spirometry conducted according to internationally accepted standards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) at (5 Min - 4 h), (5 Min - 1 h) (1 h - 4 h) Measured on Day 1, 2 Weeks (Day 14)&amp;12 Weeks (Day 84)</measure>
    <time_frame>Day 1, 2 Weeks, 12 Weeks</time_frame>
    <description>Forced Expiratory Volume in 1 second (FEV1)/Area Under the Curve(AUC) was measured via spirometry conducted according to internationally accepted standards.FEV1 AUC(5 min - 4 h), (5 min - 1 h) and (1 h - 4 h) are measured at Day 1, 2 Weeks (Day 14) and 12 Weeks (Day84) and defined as average of FEV1 at specified timepoints above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Forced Expiratory Volume in 1 Second (FEV1) at Day 1, 2 Weeks (Day 14), 12 Weeks (Day 84)</measure>
    <time_frame>Day 1, 2 weeks (Day 14), 12 weeks (Day 84)</time_frame>
    <description>Peak Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Peak FEV1 is defined as the maximum FEV1 during the first 4 h post morning dosing at Day 1, 2Weeks and 12 Weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire 5 (ACQ-5) After 4 Weeks (Day 29) and After 8 Weeks (Day 57) of Treatment</measure>
    <time_frame>after 4 weeks (Day 29) and after 8 weeks (Day 57)</time_frame>
    <description>The ACQ-5 is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze. Each item is graded on a scale of 0-6 and the questions are equally weighted. The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning and Evening Peak Expiratory Flow Rate (PEFR) Over 12 Weeks of Treatment. This is LS Mean of the Treatment Period.</measure>
    <time_frame>baseline, 4weeks, 8 weeks and 12 weeks</time_frame>
    <description>PEFR is measured with portable spirometer by participants every morning and evening at home.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Usage of Rescue Medication (Short Acting β2-agonist) Over 12 Weeks of Treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants record the number of puffs of rescue medication taken in the previous 12 hours in the morning and nighttime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Quality of Life Questionnaire (AQLQ(S)) After 4 Weeks (Day 29) and 12 Weeks (Day 85) of Treatment</measure>
    <time_frame>4 Weeks, 12 Weeks</time_frame>
    <description>The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments in asthma. Patients are asked to score each item on a 7-point scale based on the experience of last 2 weeks. The overall AQLQ score is the mean response to all 32 questions. Therefore, the possible highest score (better) would be 7 and the lowest (worse) would be 1. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and &gt; 1.5 as marked clinically important differences for any individual domain or for the overall summary score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Asthma Exacerbation (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>Duration of treatment until first asthma exacerbation by severity of exacerbation. A severe asthma exacerbation is systemic corticosteroids (SCS) use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Annual Rate of Asthma Exacerbations (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>Annual incidence rate of asthma exacerbation by severity of exacerbation. The number of asthma exacerbation is used to calculate annual incidence rate. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations. Number of the asthma exacerbation will be analyzed by the negative binomial regression including treatment, history of asthma exacerbation in the 12 months prior to screening and region as factors and FEV1 prior to inhalation and FEV1 30 min post inhalation of salbutamol/albuterol (components of SABA reversibility) as covariates. The estimates are obtained from the model and so we cannot specify a formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Asthma Exacerbations (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>Duration of asthma exacerbations by severity of exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Patients With at Least One Asthma Exacerbation (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>The percentage of patients with at least one asthma exacerbation by severity of exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Permanent Study Discontinuation Due to Asthma Exacerbation Over the 12 Week Treatment Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>Time to permanent study discontinuation due to asthma exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Patients Who Permanently Discontinued Study Due to Asthma Exacerbation Over the 12 Week Treatment Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>The percentage of patients who permanently discontinued study due to asthma exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amounts (in Doses) of Systemic Corticosteroids Used to Treat Asthma Exacerbations Over the 12 Week Treatment Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total amounts (in doses) of systemic corticosteroids (SCS) used to treat asthma exacerbations.SCS includes Intramuscular (IM), Intravenous (IV) and Oral. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Indacaterol Concentrations at Day 1 and Day 14</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Maximum plasma concentration after drug administration (Cmax) was measured for indacaterol acetate 75 µg and indacaterol acetate 150 µg for Pharmacokinetic (PK) Subgroup</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">335</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>indacaterol acetate 75 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler
Background therapy: mometasone furoate 200 mcg od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>indacaterol acetate 150 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler
Background therapy: mometasone furoate 200 mcg od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo delivered via Concept 1 inhaler
Background therapy: mometasone furoate 200 mcg od</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indacaterol</intervention_name>
    <description>indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler</description>
    <arm_group_label>indacaterol acetate 75 µg</arm_group_label>
    <arm_group_label>indacaterol acetate 150 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo delivered via Concept 1 inhaler</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate</intervention_name>
    <description>via Twisthaler inhaler</description>
    <arm_group_label>indacaterol acetate 75 µg</arm_group_label>
    <arm_group_label>indacaterol acetate 150 µg</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with persistent asthma, diagnosed according to GINA 2010 guideline and who
             additionally meet the following criteria:

          -  Patients who are receiving ICS treatment in a stable regimen for ≥ 4 weeks

          -  Patients with a pre-bronchodilator FEV1 value of ≥ 40% and ≤ 80% of predicted normal
             value

          -  Patients who demonstrate an increase of &gt;= 12% and 200 mL in FEV1

          -  ACQ-5 score ≥ 1.5

        Exclusion Criteria:

          -  Patients who are current smokers or have a smoking history of greater than 10 pack
             years (defined as the number of packs of 20 cigarettes smoked per day multiplied by
             number of years the patient smoked).

          -  Patients with chronic lung disease, including COPD, pulmonary tuberculosis,
             bronchiectasis, sarcoidosis, interstitial lung disease and cystic fibrosis.

          -  Patients with any chronic conditions affecting the respiratory tract (e.g., chronic
             sinusitis) which in the opinion of the investigator may interfere with the study
             evaluation or optimal participation in the study.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lovech</city>
        <zip>5500</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1234</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1463</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varna</city>
        <zip>9020</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Downsview</city>
        <state>Ontario</state>
        <zip>M3N 2Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grimsby</city>
        <state>Ontario</state>
        <zip>L3M 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woodstock</city>
        <state>Ontario</state>
        <zip>N4S 5P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Romuald</city>
        <state>Quebec</state>
        <zip>G6W 5M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Woerishofen</city>
        <zip>86825</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dortmund</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81677</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiesloch</city>
        <zip>69168</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yanagawa</city>
        <state>Fukuoka</state>
        <zip>832-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Obihiro</city>
        <state>Hokkaido</state>
        <zip>080-0805</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>060-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ako-shi</city>
        <state>Hyogo-Ken</state>
        <zip>678-0241</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Himeji-city</city>
        <state>Hyogo</state>
        <zip>672-8064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Naka-gun</city>
        <state>Ibaraki</state>
        <zip>319-1113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sakaide</city>
        <state>Kagawa</state>
        <zip>762-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto-Fu</state>
        <zip>615-8256</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oita-shi</city>
        <state>Oita-Ken</state>
        <zip>870-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <zip>874-0937</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kishiwada</city>
        <state>Osaka</state>
        <zip>596-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Machida-shi</city>
        <state>Tokyo-To</state>
        <zip>194-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo-To</state>
        <zip>144-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cyuo-ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiyose-city</city>
        <state>Tokyo</state>
        <zip>204-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>158-0097</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yonezawa</city>
        <state>Yamagata</state>
        <zip>992-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1394</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gifu</city>
        <zip>502-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cheongju</city>
        <state>Chungbuk</state>
        <zip>361 711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon-Do</state>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>110 744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>100-032</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bienkowka</city>
        <zip>34-212</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-046</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-958</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-023</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Znin</city>
        <zip>88-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <state>Slovak Republic</state>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bardejov</city>
        <state>Slovak Republic</state>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Levice</city>
        <state>Slovak republic</state>
        <zip>934 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dunajska Streda</city>
        <zip>929 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Komarno</city>
        <zip>945 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liptovsky Hradok</city>
        <zip>033 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liptovsky Mikulas</city>
        <zip>031 23</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nove Zamky</city>
        <zip>940 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>979 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spisská Nová Ves</city>
        <zip>052 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Topolcany</city>
        <zip>955 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vysne Hagy</city>
        <zip>5984</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zvolen</city>
        <zip>960 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2012</study_first_posted>
  <results_first_submitted>June 27, 2014</results_first_submitted>
  <results_first_submitted_qc>August 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2014</results_first_posted>
  <last_update_submitted>January 15, 2015</last_update_submitted>
  <last_update_submitted_qc>January 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Indacaterol Acetate 75 µg</title>
          <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
        </group>
        <group group_id="P2">
          <title>Indacaterol Acetate 150 µg</title>
          <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Indacaterol Acetate 75 µg</title>
          <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
        </group>
        <group group_id="B2">
          <title>Indacaterol Acetate 150 µg</title>
          <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="116"/>
            <count group_id="B4" value="335"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="14.74"/>
                    <measurement group_id="B2" value="48.1" spread="13.53"/>
                    <measurement group_id="B3" value="49.8" spread="12.96"/>
                    <measurement group_id="B4" value="49.6" spread="13.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Forced Expiratory Volume in One Second (FEV1) After 12 Weeks (Day 85)</title>
        <description>Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose after 12 weeks (Day 85)</description>
        <time_frame>after 12 weeks (Day 85)</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in One Second (FEV1) After 12 Weeks (Day 85)</title>
          <description>Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose after 12 weeks (Day 85)</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.190" spread="0.0283"/>
                    <measurement group_id="O2" value="2.216" spread="0.0281"/>
                    <measurement group_id="O3" value="2.110" spread="0.0275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Questionnaire 5 (ACQ-5) After 12 Weeks (Day 85)</title>
        <description>The Asthma Control Questionnaire (ACQ-5) is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze. The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). A negative change in score indicates improvement in symptoms. MIXED model: Change from baseline in ACQ-5 = treatment + gender + baseline ACQ-5 score + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.</description>
        <time_frame>aftert 12 weeks (Day 85)</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Questionnaire 5 (ACQ-5) After 12 Weeks (Day 85)</title>
          <description>The Asthma Control Questionnaire (ACQ-5) is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze. The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). A negative change in score indicates improvement in symptoms. MIXED model: Change from baseline in ACQ-5 = treatment + gender + baseline ACQ-5 score + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.094"/>
                    <measurement group_id="O2" value="1.42" spread="0.093"/>
                    <measurement group_id="O3" value="1.32" spread="0.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Expiratory Volume in One Second (FEV1) After 2 Weeks (Day 15), 4 Weeks (Day 29), and 8 Weeks (Day 57) of Treatment.</title>
        <description>Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose after 2 weeks (Day 15), 4 weeks (Day 29), and 8 weeks (Day 57) of treatment.</description>
        <time_frame>Day 15, Day 29 and Day 57</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in One Second (FEV1) After 2 Weeks (Day 15), 4 Weeks (Day 29), and 8 Weeks (Day 57) of Treatment.</title>
          <description>Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose after 2 weeks (Day 15), 4 weeks (Day 29), and 8 weeks (Day 57) of treatment.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.169" spread="0.0259"/>
                    <measurement group_id="O2" value="2.198" spread="0.0260"/>
                    <measurement group_id="O3" value="2.069" spread="0.0253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.180" spread="0.0274"/>
                    <measurement group_id="O2" value="2.196" spread="0.0276"/>
                    <measurement group_id="O3" value="2.057" spread="0.0266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.180" spread="0.0281"/>
                    <measurement group_id="O2" value="2.227" spread="0.0281"/>
                    <measurement group_id="O3" value="2.099" spread="0.0273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 at All Time Points</title>
        <description>Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards. FVC is measured on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 at all time points</description>
        <time_frame>Day 1, Day 2, Day 14, Day 15, Day 84, Day 85</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 at All Time Points</title>
          <description>Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards. FVC is measured on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 at all time points</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 / 5 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.342" spread="0.0198"/>
                    <measurement group_id="O2" value="3.338" spread="0.0198"/>
                    <measurement group_id="O3" value="3.235" spread="0.0190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 15 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.372" spread="0.0240"/>
                    <measurement group_id="O2" value="3.348" spread="0.0241"/>
                    <measurement group_id="O3" value="3.238" spread="0.0232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 30 min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.378" spread="0.0236"/>
                    <measurement group_id="O2" value="3.367" spread="0.0236"/>
                    <measurement group_id="O3" value="3.239" spread="0.0227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 1 hr post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.356" spread="0.0237"/>
                    <measurement group_id="O2" value="3.333" spread="0.0239"/>
                    <measurement group_id="O3" value="3.241" spread="0.0229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 2 hr post-dose (n=106,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.366" spread="0.0256"/>
                    <measurement group_id="O2" value="3.367" spread="0.0258"/>
                    <measurement group_id="O3" value="3.268" spread="0.0247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 4 hr post-dose (n=107,101,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.346" spread="0.0304"/>
                    <measurement group_id="O2" value="3.342" spread="0.0307"/>
                    <measurement group_id="O3" value="3.238" spread="0.0290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 6 hr post-dose (n=24,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.299" spread="0.0545"/>
                    <measurement group_id="O2" value="3.345" spread="0.0507"/>
                    <measurement group_id="O3" value="3.280" spread="0.0509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 / 23 hr 10min post-dose (n=107,104,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.314" spread="0.0282"/>
                    <measurement group_id="O2" value="3.303" spread="0.0290"/>
                    <measurement group_id="O3" value="3.254" spread="0.0279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 / 23 hr 45min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.313" spread="0.0309"/>
                    <measurement group_id="O2" value="3.341" spread="0.0314"/>
                    <measurement group_id="O3" value="3.269" spread="0.0297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 5 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.404" spread="0.0327"/>
                    <measurement group_id="O2" value="3.364" spread="0.0332"/>
                    <measurement group_id="O3" value="3.212" spread="0.0326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 15 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.397" spread="0.0340"/>
                    <measurement group_id="O2" value="3.377" spread="0.0343"/>
                    <measurement group_id="O3" value="3.213" spread="0.0336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 30 min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.412" spread="0.0341"/>
                    <measurement group_id="O2" value="3.389" spread="0.0345"/>
                    <measurement group_id="O3" value="3.246" spread="0.0336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 1 hr post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.408" spread="0.0324"/>
                    <measurement group_id="O2" value="3.379" spread="0.0327"/>
                    <measurement group_id="O3" value="3.206" spread="0.0319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 2 hr post-dose (n=106,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.402" spread="0.0325"/>
                    <measurement group_id="O2" value="3.395" spread="0.0329"/>
                    <measurement group_id="O3" value="3.207" spread="0.0323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 4 hr post-dose (n=107,101,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.368" spread="0.0329"/>
                    <measurement group_id="O2" value="3.338" spread="0.0336"/>
                    <measurement group_id="O3" value="3.217" spread="0.0323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 6 hr post-dose (n=24,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.332" spread="0.0620"/>
                    <measurement group_id="O2" value="3.426" spread="0.0584"/>
                    <measurement group_id="O3" value="3.257" spread="0.0602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 / 23 hr 10min post-dose (n=107,104,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.324" spread="0.0298"/>
                    <measurement group_id="O2" value="3.311" spread="0.0302"/>
                    <measurement group_id="O3" value="3.237" spread="0.0294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 / 23 hr 45min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.347" spread="0.0307"/>
                    <measurement group_id="O2" value="3.313" spread="0.0311"/>
                    <measurement group_id="O3" value="3.260" spread="0.0301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 5 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.381" spread="0.0331"/>
                    <measurement group_id="O2" value="3.374" spread="0.0335"/>
                    <measurement group_id="O3" value="3.263" spread="0.0331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 15 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.393" spread="0.0353"/>
                    <measurement group_id="O2" value="3.392" spread="0.0355"/>
                    <measurement group_id="O3" value="3.275" spread="0.0351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 30 min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.424" spread="0.0350"/>
                    <measurement group_id="O2" value="3.399" spread="0.0352"/>
                    <measurement group_id="O3" value="3.282" spread="0.0349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 1hr post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.394" spread="0.0339"/>
                    <measurement group_id="O2" value="3.393" spread="0.0346"/>
                    <measurement group_id="O3" value="3.262" spread="0.0336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 2 hr post-dose (n=106,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.413" spread="0.0334"/>
                    <measurement group_id="O2" value="3.382" spread="0.0335"/>
                    <measurement group_id="O3" value="3.292" spread="0.0332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 4 hr post-dose (n=106,101,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.346" spread="0.0350"/>
                    <measurement group_id="O2" value="3.363" spread="0.0356"/>
                    <measurement group_id="O3" value="3.257" spread="0.0349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 / 23 hr 10min post-dose (n=107,104,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.350" spread="0.0342"/>
                    <measurement group_id="O2" value="3.300" spread="0.0347"/>
                    <measurement group_id="O3" value="3.287" spread="0.0339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 / 23 hr 45min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.343" spread="0.0367"/>
                    <measurement group_id="O2" value="3.321" spread="0.0368"/>
                    <measurement group_id="O3" value="3.294" spread="0.0360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1)/ Forced Vital Capacity (FVC) on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85</title>
        <description>Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards.</description>
        <time_frame>Day 1, Day 2, Day 14, Day 15, Day 84, Day 85</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1)/ Forced Vital Capacity (FVC) on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85</title>
          <description>Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 / 5 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.608" spread="0.3659"/>
                    <measurement group_id="O2" value="66.049" spread="0.3641"/>
                    <measurement group_id="O3" value="63.461" spread="0.3508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 15 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.602" spread="0.3854"/>
                    <measurement group_id="O2" value="67.039" spread="0.3898"/>
                    <measurement group_id="O3" value="63.537" spread="0.3759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 30 min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.738" spread="0.4626"/>
                    <measurement group_id="O2" value="67.189" spread="0.4607"/>
                    <measurement group_id="O3" value="63.767" spread="0.4454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 1 hr post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.089" spread="0.4465"/>
                    <measurement group_id="O2" value="67.620" spread="0.4485"/>
                    <measurement group_id="O3" value="63.744" spread="0.4298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 2 hr post-dose (n=106,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.607" spread="0.4705"/>
                    <measurement group_id="O2" value="67.824" spread="0.4727"/>
                    <measurement group_id="O3" value="64.141" spread="0.4534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 4 hr post-dose (n=107,101,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.094" spread="0.5098"/>
                    <measurement group_id="O2" value="67.968" spread="0.5137"/>
                    <measurement group_id="O3" value="64.212" spread="0.4871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 6 hr post-dose (n=24,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.716" spread="0.9815"/>
                    <measurement group_id="O2" value="68.846" spread="0.9220"/>
                    <measurement group_id="O3" value="63.773" spread="0.9135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 / 23 hr 10min post-dose (n=107,104,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.465" spread="0.5112"/>
                    <measurement group_id="O2" value="66.942" spread="0.5197"/>
                    <measurement group_id="O3" value="63.822" spread="0.5006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 / 23 hr 45min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.809" spread="0.5299"/>
                    <measurement group_id="O2" value="66.791" spread="0.5323"/>
                    <measurement group_id="O3" value="63.741" spread="0.5057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 5 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.548" spread="0.5102"/>
                    <measurement group_id="O2" value="67.366" spread="0.5172"/>
                    <measurement group_id="O3" value="64.362" spread="0.5075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 15 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.187" spread="0.5042"/>
                    <measurement group_id="O2" value="67.577" spread="0.5093"/>
                    <measurement group_id="O3" value="64.702" spread="0.4986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 30 min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.024" spread="0.5601"/>
                    <measurement group_id="O2" value="67.765" spread="0.5633"/>
                    <measurement group_id="O3" value="64.192" spread="0.5476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 1 hr post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.100" spread="0.5446"/>
                    <measurement group_id="O2" value="68.262" spread="0.5476"/>
                    <measurement group_id="O3" value="64.383" spread="0.5327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 2 hr post-dose (n=106,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.538" spread="0.5486"/>
                    <measurement group_id="O2" value="68.397" spread="0.5540"/>
                    <measurement group_id="O3" value="64.617" spread="0.5431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 4 hr post-dose (n=107,101,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.866" spread="0.5763"/>
                    <measurement group_id="O2" value="68.044" spread="0.5871"/>
                    <measurement group_id="O3" value="64.426" spread="0.5632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 6 hr post-dose (n=24,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.792" spread="1.0246"/>
                    <measurement group_id="O2" value="67.346" spread="0.9676"/>
                    <measurement group_id="O3" value="64.167" spread="0.9834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 / 23 hr 10min post-dose (n=107,104,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.436" spread="0.5564"/>
                    <measurement group_id="O2" value="65.930" spread="0.5597"/>
                    <measurement group_id="O3" value="64.027" spread="0.5455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 / 23 hr 45min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.606" spread="0.5871"/>
                    <measurement group_id="O2" value="66.435" spread="0.5887"/>
                    <measurement group_id="O3" value="63.726" spread="0.5729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 5 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.040" spread="0.5442"/>
                    <measurement group_id="O2" value="67.762" spread="0.5498"/>
                    <measurement group_id="O3" value="64.850" spread="0.5422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 15 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.162" spread="0.5671"/>
                    <measurement group_id="O2" value="67.907" spread="0.5719"/>
                    <measurement group_id="O3" value="65.074" spread="0.5646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 30 min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.936" spread="0.6017"/>
                    <measurement group_id="O2" value="67.865" spread="0.6031"/>
                    <measurement group_id="O3" value="64.848" spread="0.5966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 1hr post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.394" spread="0.0339"/>
                    <measurement group_id="O2" value="3.393" spread="0.0346"/>
                    <measurement group_id="O3" value="3.262" spread="0.0336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 2 hr post-dose (n=106,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.413" spread="0.0334"/>
                    <measurement group_id="O2" value="3.382" spread="0.0335"/>
                    <measurement group_id="O3" value="3.292" spread="0.0332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 4 hr post-dose (n=106,101,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.346" spread="0.0350"/>
                    <measurement group_id="O2" value="3.363" spread="0.0356"/>
                    <measurement group_id="O3" value="3.257" spread="0.0349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 / 23 hr 10min post-dose (n=107,104,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.350" spread="0.0342"/>
                    <measurement group_id="O2" value="3.300" spread="0.0347"/>
                    <measurement group_id="O3" value="3.287" spread="0.0339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 / 23 hr 45min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.343" spread="0.0367"/>
                    <measurement group_id="O2" value="3.321" spread="0.0368"/>
                    <measurement group_id="O3" value="3.294" spread="0.0360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Flow (FEF 25-75% )on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85</title>
        <description>Forced Expiratory Flow (FEF 25-75%) was measured via spirometry conducted according to internationally accepted standards.</description>
        <time_frame>Day 1, Day 2, Day 14, Day 15, Day 84, Day 85</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Flow (FEF 25-75% )on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85</title>
          <description>Forced Expiratory Flow (FEF 25-75%) was measured via spirometry conducted according to internationally accepted standards.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>liters/second</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 / 5 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.420" spread="0.0237"/>
                    <measurement group_id="O2" value="1.485" spread="0.0235"/>
                    <measurement group_id="O3" value="1.295" spread="0.0226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 15 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.449" spread="0.0254"/>
                    <measurement group_id="O2" value="1.563" spread="0.0256"/>
                    <measurement group_id="O3" value="1.295" spread="0.0247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 30 min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.467" spread="0.0290"/>
                    <measurement group_id="O2" value="1.568" spread="0.0290"/>
                    <measurement group_id="O3" value="1.310" spread="0.0280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 1 hr post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.471" spread="0.0307"/>
                    <measurement group_id="O2" value="1.594" spread="0.0309"/>
                    <measurement group_id="O3" value="1.297" spread="0.0296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 2 hr post-dose (n=106,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.508" spread="0.0307"/>
                    <measurement group_id="O2" value="1.632" spread="0.0310"/>
                    <measurement group_id="O3" value="1.348" spread="0.0297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 4 hr post-dose (n=107,101,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.479" spread="0.0327"/>
                    <measurement group_id="O2" value="1.625" spread="0.0331"/>
                    <measurement group_id="O3" value="1.329" spread="0.0313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 6 hr post-dose (n=24,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.364" spread="0.0889"/>
                    <measurement group_id="O2" value="1.620" spread="0.0840"/>
                    <measurement group_id="O3" value="1.332" spread="0.0832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 / 23 hr 10min post-dose (n=107,104,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.407" spread="0.0322"/>
                    <measurement group_id="O2" value="1.520" spread="0.0328"/>
                    <measurement group_id="O3" value="1.310" spread="0.0315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 / 23 hr 45min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.436" spread="0.0399"/>
                    <measurement group_id="O2" value="1.524" spread="0.0401"/>
                    <measurement group_id="O3" value="1.326" spread="0.0382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 5 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.505" spread="0.0350"/>
                    <measurement group_id="O2" value="1.571" spread="0.0354"/>
                    <measurement group_id="O3" value="1.318" spread="0.0348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 15 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.540" spread="0.0366"/>
                    <measurement group_id="O2" value="1.597" spread="0.0370"/>
                    <measurement group_id="O3" value="1.351" spread="0.0362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 30 min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.532" spread="0.0383"/>
                    <measurement group_id="O2" value="1.607" spread="0.0386"/>
                    <measurement group_id="O3" value="1.336" spread="0.0376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 1 hr post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.569" spread="0.0400"/>
                    <measurement group_id="O2" value="1.664" spread="0.0402"/>
                    <measurement group_id="O3" value="1.343" spread="0.0391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 2 hr post-dose (n=106,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.551" spread="0.0380"/>
                    <measurement group_id="O2" value="1.676" spread="0.0385"/>
                    <measurement group_id="O3" value="1.338" spread="0.0379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 4 hr post-dose (n=107,101,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.526" spread="0.0434"/>
                    <measurement group_id="O2" value="1.628" spread="0.0445"/>
                    <measurement group_id="O3" value="1.339" spread="0.0426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 / 6 hr post-dose (n=24,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.370" spread="0.0843"/>
                    <measurement group_id="O2" value="1.519" spread="0.0792"/>
                    <measurement group_id="O3" value="1.363" spread="0.0808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 / 23 hr 10min post-dose (n=107,104,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.421" spread="0.0383"/>
                    <measurement group_id="O2" value="1.442" spread="0.0386"/>
                    <measurement group_id="O3" value="1.315" spread="0.0377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 / 23 hr 45min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.430" spread="0.0431"/>
                    <measurement group_id="O2" value="1.492" spread="0.0431"/>
                    <measurement group_id="O3" value="1.319" spread="0.0420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 5 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.535" spread="0.0391"/>
                    <measurement group_id="O2" value="1.627" spread="0.0394"/>
                    <measurement group_id="O3" value="1.363" spread="0.0390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 15 min post-dose (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.530" spread="0.0393"/>
                    <measurement group_id="O2" value="1.675" spread="0.0396"/>
                    <measurement group_id="O3" value="1.372" spread="0.0392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 30 min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.548" spread="0.0412"/>
                    <measurement group_id="O2" value="10659" spread="0.0414"/>
                    <measurement group_id="O3" value="1.368" spread="0.0411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 1hr post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.578" spread="0.0408"/>
                    <measurement group_id="O2" value="1.687" spread="0.0415"/>
                    <measurement group_id="O3" value="1.404" spread="0.0404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 2 hr post-dose (n=106,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.571" spread="0.0409"/>
                    <measurement group_id="O2" value="1.704" spread="0.0411"/>
                    <measurement group_id="O3" value="1.382" spread="0.0409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 4 hr post-dose (n=106,101,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.548" spread="0.0398"/>
                    <measurement group_id="O2" value="1.648" spread="0.0405"/>
                    <measurement group_id="O3" value="1.350" spread="0.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 / 23 hr 10min post-dose (n=107,104,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.437" spread="0.0378"/>
                    <measurement group_id="O2" value="1.507" spread="0.0380"/>
                    <measurement group_id="O3" value="1.328" spread="0.0373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 / 23 hr 45min post-dose (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.476" spread="0.0428"/>
                    <measurement group_id="O2" value="1.496" spread="0.0427"/>
                    <measurement group_id="O3" value="1.378" spread="0.0418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) at (5 Min - 4 h), (5 Min - 1 h) (1 h - 4 h) Measured on Day 1, 2 Weeks (Day 14)&amp;12 Weeks (Day 84)</title>
        <description>Forced Expiratory Volume in 1 second (FEV1)/Area Under the Curve(AUC) was measured via spirometry conducted according to internationally accepted standards.FEV1 AUC(5 min - 4 h), (5 min - 1 h) and (1 h - 4 h) are measured at Day 1, 2 Weeks (Day 14) and 12 Weeks (Day84) and defined as average of FEV1 at specified timepoints above.</description>
        <time_frame>Day 1, 2 Weeks, 12 Weeks</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) at (5 Min - 4 h), (5 Min - 1 h) (1 h - 4 h) Measured on Day 1, 2 Weeks (Day 14)&amp;12 Weeks (Day 84)</title>
          <description>Forced Expiratory Volume in 1 second (FEV1)/Area Under the Curve(AUC) was measured via spirometry conducted according to internationally accepted standards.FEV1 AUC(5 min - 4 h), (5 min - 1 h) and (1 h - 4 h) are measured at Day 1, 2 Weeks (Day 14) and 12 Weeks (Day84) and defined as average of FEV1 at specified timepoints above.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (5min-4h) (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.209" spread="0.0170"/>
                    <measurement group_id="O2" value="2.274" spread="0.0169"/>
                    <measurement group_id="O3" value="2.077" spread="0.0163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (5min-1h) (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.198" spread="0.0165"/>
                    <measurement group_id="O2" value="2.253" spread="0.0164"/>
                    <measurement group_id="O3" value="2.059" spread="0.0158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (1h-4h) (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.212" spread="0.0182"/>
                    <measurement group_id="O2" value="2.284" spread="0.0183"/>
                    <measurement group_id="O3" value="2.082" spread="0.0175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (5min-4h) (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.265" spread="0.0244"/>
                    <measurement group_id="O2" value="2.313" spread="0.0246"/>
                    <measurement group_id="O3" value="2.074" spread="0.0240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (5min-1h) (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.267" spread="0.0245"/>
                    <measurement group_id="O2" value="2.299" spread="0.0246"/>
                    <measurement group_id="O3" value="2.069" spread="0.0241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (1h-4h) (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.262" spread="0.0247"/>
                    <measurement group_id="O2" value="2.318" spread="0.0250"/>
                    <measurement group_id="O3" value="2.066" spread="0.0244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (5min-4h) (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.264" spread="0.0259"/>
                    <measurement group_id="O2" value="2.322" spread="0.0260"/>
                    <measurement group_id="O3" value="2.132" spread="0.0257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (5min-1h) (n=107,105,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.265" spread="0.0271"/>
                    <measurement group_id="O2" value="2.321" spread="0.0272"/>
                    <measurement group_id="O3" value="2.119" spread="0.0270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (1h-4h) (n=107,104,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.263" spread="0.0258"/>
                    <measurement group_id="O2" value="2.322" spread="0.0260"/>
                    <measurement group_id="O3" value="2.130" spread="0.0257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Forced Expiratory Volume in 1 Second (FEV1) at Day 1, 2 Weeks (Day 14), 12 Weeks (Day 84)</title>
        <description>Peak Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Peak FEV1 is defined as the maximum FEV1 during the first 4 h post morning dosing at Day 1, 2Weeks and 12 Weeks.</description>
        <time_frame>Day 1, 2 weeks (Day 14), 12 weeks (Day 84)</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Forced Expiratory Volume in 1 Second (FEV1) at Day 1, 2 Weeks (Day 14), 12 Weeks (Day 84)</title>
          <description>Peak Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Peak FEV1 is defined as the maximum FEV1 during the first 4 h post morning dosing at Day 1, 2Weeks and 12 Weeks.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.287" spread="0.0183"/>
                    <measurement group_id="O2" value="2.353" spread="0.0182"/>
                    <measurement group_id="O3" value="2.172" spread="0.0176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.345" spread="0.0252"/>
                    <measurement group_id="O2" value="2.387" spread="0.0254"/>
                    <measurement group_id="O3" value="2.165" spread="0.0248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.345" spread="0.0272"/>
                    <measurement group_id="O2" value="2.403" spread="0.0273"/>
                    <measurement group_id="O3" value="2.215" spread="0.0270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Questionnaire 5 (ACQ-5) After 4 Weeks (Day 29) and After 8 Weeks (Day 57) of Treatment</title>
        <description>The ACQ-5 is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze. Each item is graded on a scale of 0-6 and the questions are equally weighted. The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).</description>
        <time_frame>after 4 weeks (Day 29) and after 8 weeks (Day 57)</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Questionnaire 5 (ACQ-5) After 4 Weeks (Day 29) and After 8 Weeks (Day 57) of Treatment</title>
          <description>The ACQ-5 is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze. Each item is graded on a scale of 0-6 and the questions are equally weighted. The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29 (n=103, 104, 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.088"/>
                    <measurement group_id="O2" value="1.39" spread="0.088"/>
                    <measurement group_id="O3" value="1.55" spread="0.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n= 103, 104, 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.093"/>
                    <measurement group_id="O2" value="1.29" spread="0.093"/>
                    <measurement group_id="O3" value="1.46" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning and Evening Peak Expiratory Flow Rate (PEFR) Over 12 Weeks of Treatment. This is LS Mean of the Treatment Period.</title>
        <description>PEFR is measured with portable spirometer by participants every morning and evening at home.</description>
        <time_frame>baseline, 4weeks, 8 weeks and 12 weeks</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Morning and Evening Peak Expiratory Flow Rate (PEFR) Over 12 Weeks of Treatment. This is LS Mean of the Treatment Period.</title>
          <description>PEFR is measured with portable spirometer by participants every morning and evening at home.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>liters/second</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morning Baseline - &lt;4 weeks (n=104,100,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326.98" spread="3.741"/>
                    <measurement group_id="O2" value="335.44" spread="3.842"/>
                    <measurement group_id="O3" value="307.68" spread="3.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening baseline - &lt;4 weeks (n=104,100,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332.96" spread="3.477"/>
                    <measurement group_id="O2" value="345.99" spread="3.587"/>
                    <measurement group_id="O3" value="312.42" spread="3.545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning 4 weeks - &lt;8 weeks (n=104,100,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328.45" spread="4.374"/>
                    <measurement group_id="O2" value="338.23" spread="4.466"/>
                    <measurement group_id="O3" value="315.60" spread="4.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening 4 weeks - &lt;8 weeks (n=104,100,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333.36" spread="4.221"/>
                    <measurement group_id="O2" value="344.63" spread="4.323"/>
                    <measurement group_id="O3" value="313.31" spread="4.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning 8 weeks - &lt;12 weeks (n=104,100,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329.85" spread="4.699"/>
                    <measurement group_id="O2" value="334.83" spread="4.783"/>
                    <measurement group_id="O3" value="317.03" spread="4.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening 8 weeks - &lt;12 weeks (n=104,100,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332.61" spread="4.628"/>
                    <measurement group_id="O2" value="342.40" spread="4.718"/>
                    <measurement group_id="O3" value="316.28" spread="4.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Usage of Rescue Medication (Short Acting β2-agonist) Over 12 Weeks of Treatment</title>
        <description>Participants record the number of puffs of rescue medication taken in the previous 12 hours in the morning and nighttime.</description>
        <time_frame>12 weeks</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>The Usage of Rescue Medication (Short Acting β2-agonist) Over 12 Weeks of Treatment</title>
          <description>Participants record the number of puffs of rescue medication taken in the previous 12 hours in the morning and nighttime.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>number of puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean daily number of puffs (n=105, 102, 105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.132"/>
                    <measurement group_id="O2" value="0.99" spread="0.136"/>
                    <measurement group_id="O3" value="1.31" spread="0.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Daytime number of puffs (n=103, 99, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.074"/>
                    <measurement group_id="O2" value="0.55" spread="0.077"/>
                    <measurement group_id="O3" value="0.73" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean nighttime number of puffs (n=104, 100, 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.063"/>
                    <measurement group_id="O2" value="0.47" spread="0.065"/>
                    <measurement group_id="O3" value="0.64" spread="0.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Quality of Life Questionnaire (AQLQ(S)) After 4 Weeks (Day 29) and 12 Weeks (Day 85) of Treatment</title>
        <description>The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments in asthma. Patients are asked to score each item on a 7-point scale based on the experience of last 2 weeks. The overall AQLQ score is the mean response to all 32 questions. Therefore, the possible highest score (better) would be 7 and the lowest (worse) would be 1. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and &gt; 1.5 as marked clinically important differences for any individual domain or for the overall summary score.</description>
        <time_frame>4 Weeks, 12 Weeks</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Quality of Life Questionnaire (AQLQ(S)) After 4 Weeks (Day 29) and 12 Weeks (Day 85) of Treatment</title>
          <description>The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments in asthma. Patients are asked to score each item on a 7-point scale based on the experience of last 2 weeks. The overall AQLQ score is the mean response to all 32 questions. Therefore, the possible highest score (better) would be 7 and the lowest (worse) would be 1. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and &gt; 1.5 as marked clinically important differences for any individual domain or for the overall summary score.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29 (n=103,104, 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.52" spread="0.082"/>
                    <measurement group_id="O2" value="5.48" spread="0.082"/>
                    <measurement group_id="O3" value="5.38" spread="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n=103,104, 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.64" spread="0.088"/>
                    <measurement group_id="O2" value="5.47" spread="0.087"/>
                    <measurement group_id="O3" value="5.60" spread="0.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Asthma Exacerbation (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period</title>
        <description>Duration of treatment until first asthma exacerbation by severity of exacerbation. A severe asthma exacerbation is systemic corticosteroids (SCS) use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
        <time_frame>12 weeks</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Asthma Exacerbation (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period</title>
          <description>Duration of treatment until first asthma exacerbation by severity of exacerbation. A severe asthma exacerbation is systemic corticosteroids (SCS) use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate or Severe exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were too few events to calculate the median.</measurement>
                    <measurement group_id="O2" value="NA">There were too few events to calculate the median.</measurement>
                    <measurement group_id="O3" value="NA">There were too few events to calculate the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Asthma Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were too few events to calculate the median.</measurement>
                    <measurement group_id="O2" value="NA">There were too few events to calculate the median.</measurement>
                    <measurement group_id="O3" value="NA">There were too few events to calculate the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild Asthma Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were too few events to calculate the median.</measurement>
                    <measurement group_id="O2" value="NA">There were too few events to calculate the median.</measurement>
                    <measurement group_id="O3" value="NA">There were too few events to calculate the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Asthma Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were too few events to calculate the median.</measurement>
                    <measurement group_id="O2" value="NA">There were too few events to calculate the median.</measurement>
                    <measurement group_id="O3" value="NA">There were too few events to calculate the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Asthma Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were too few events to calculate the median.</measurement>
                    <measurement group_id="O2" value="NA">There were too few events to calculate the median.</measurement>
                    <measurement group_id="O3" value="NA">There were too few events to calculate the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Annual Rate of Asthma Exacerbations (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period</title>
        <description>Annual incidence rate of asthma exacerbation by severity of exacerbation. The number of asthma exacerbation is used to calculate annual incidence rate. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations. Number of the asthma exacerbation will be analyzed by the negative binomial regression including treatment, history of asthma exacerbation in the 12 months prior to screening and region as factors and FEV1 prior to inhalation and FEV1 30 min post inhalation of salbutamol/albuterol (components of SABA reversibility) as covariates. The estimates are obtained from the model and so we cannot specify a formula.</description>
        <time_frame>12 weeks</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>The Annual Rate of Asthma Exacerbations (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period</title>
          <description>Annual incidence rate of asthma exacerbation by severity of exacerbation. The number of asthma exacerbation is used to calculate annual incidence rate. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations. Number of the asthma exacerbation will be analyzed by the negative binomial regression including treatment, history of asthma exacerbation in the 12 months prior to screening and region as factors and FEV1 prior to inhalation and FEV1 30 min post inhalation of salbutamol/albuterol (components of SABA reversibility) as covariates. The estimates are obtained from the model and so we cannot specify a formula.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units># of exacerbations</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate or Severe Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.315" lower_limit="0.1184" upper_limit="0.8387"/>
                    <measurement group_id="O2" value="0.353" lower_limit="0.1373" upper_limit="0.9053"/>
                    <measurement group_id="O3" value="0.352" lower_limit="0.1406" upper_limit="0.8805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.421" lower_limit="0.1711" upper_limit="1.0358"/>
                    <measurement group_id="O2" value="0.569" lower_limit="0.2389" upper_limit="1.3553"/>
                    <measurement group_id="O3" value="0.788" lower_limit="0.3486" upper_limit="1.7827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild Asthma Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.0000">upper limit infinity</measurement>
                    <measurement group_id="O2" value="0.001" lower_limit="0.0000">upper limit infinity</measurement>
                    <measurement group_id="O3" value="0.001" lower_limit="0.000">upper limit infinity</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Asthma Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.225" lower_limit="0.0790" upper_limit="0.6403"/>
                    <measurement group_id="O2" value="0.320" lower_limit="0.1239" upper_limit="0.8251"/>
                    <measurement group_id="O3" value="0.274" lower_limit="0.1017" upper_limit="0.7387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Asthma Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.0000">upper limit infinity</measurement>
                    <measurement group_id="O2" value="0.000" lower_limit="0.000">upper limit infinity</measurement>
                    <measurement group_id="O3" value="0.000" lower_limit="0.000">upper limit infinity</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Asthma Exacerbations (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period</title>
        <description>Duration of asthma exacerbations by severity of exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
        <time_frame>12 weeks</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Asthma Exacerbations (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period</title>
          <description>Duration of asthma exacerbations by severity of exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>moderate or severe exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="3.32"/>
                    <measurement group_id="O2" value="0.6" spread="2.50"/>
                    <measurement group_id="O3" value="0.8" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any asthma exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="3.88"/>
                    <measurement group_id="O2" value="0.9" spread="3.62"/>
                    <measurement group_id="O3" value="1.3" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild asthma exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="2.11"/>
                    <measurement group_id="O2" value="0.4" spread="2.47"/>
                    <measurement group_id="O3" value="0.5" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate asthma exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="3.26"/>
                    <measurement group_id="O2" value="0.6" spread="2.50"/>
                    <measurement group_id="O3" value="0.6" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe asthma exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.67"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.1" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Patients With at Least One Asthma Exacerbation (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period</title>
        <description>The percentage of patients with at least one asthma exacerbation by severity of exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
        <time_frame>12 weeks</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients With at Least One Asthma Exacerbation (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period</title>
          <description>The percentage of patients with at least one asthma exacerbation by severity of exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>moderate or severe asthma exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="5.7"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any asthma exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="8.6"/>
                    <measurement group_id="O3" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild asthma exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="3.8"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate asthma exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="5.7"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe asthma exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Permanent Study Discontinuation Due to Asthma Exacerbation Over the 12 Week Treatment Period</title>
        <description>Time to permanent study discontinuation due to asthma exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
        <time_frame>12 weeks</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Permanent Study Discontinuation Due to Asthma Exacerbation Over the 12 Week Treatment Period</title>
          <description>Time to permanent study discontinuation due to asthma exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were too few events to calculate the median.</measurement>
                    <measurement group_id="O2" value="NA">There were too few events to calculate the median.</measurement>
                    <measurement group_id="O3" value="NA">There were too few events to calculate the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Patients Who Permanently Discontinued Study Due to Asthma Exacerbation Over the 12 Week Treatment Period</title>
        <description>The percentage of patients who permanently discontinued study due to asthma exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
        <time_frame>12 weeks</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients Who Permanently Discontinued Study Due to Asthma Exacerbation Over the 12 Week Treatment Period</title>
          <description>The percentage of patients who permanently discontinued study due to asthma exacerbation. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amounts (in Doses) of Systemic Corticosteroids Used to Treat Asthma Exacerbations Over the 12 Week Treatment Period</title>
        <description>Total amounts (in doses) of systemic corticosteroids (SCS) used to treat asthma exacerbations.SCS includes Intramuscular (IM), Intravenous (IV) and Oral. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
        <time_frame>12 weeks</time_frame>
        <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amounts (in Doses) of Systemic Corticosteroids Used to Treat Asthma Exacerbations Over the 12 Week Treatment Period</title>
          <description>Total amounts (in doses) of systemic corticosteroids (SCS) used to treat asthma exacerbations.SCS includes Intramuscular (IM), Intravenous (IV) and Oral. A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.</description>
          <population>The Full Analysis Set (FAS) included all randomized who received at least one dose of study drug with available data for analysis. Participants from FAS were considered for this analysis, however for a given time point participants analyzed had a value at such timepoint.</population>
          <units>milligrams (mg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IIntramuscular - Triamcinolone Acetonide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">no participants in this treatment group took this SCS</measurement>
                    <measurement group_id="O2" value="20">SD cannot be calculated as there was only one value</measurement>
                    <measurement group_id="O3" value="0">no participants in this treatment group took this SCS</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intravenous - Betamethasone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">no participants in this treatment group took this SCS</measurement>
                    <measurement group_id="O2" value="4">SD cannot be calculated as there was only one value</measurement>
                    <measurement group_id="O3" value="4">SD cannot be calculated as there was only one value</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intravenous- Hydrocortisone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500">SD cannot be calculated as there was only one value</measurement>
                    <measurement group_id="O2" value="100">SD cannot be calculated as there was only one value</measurement>
                    <measurement group_id="O3" value="200">SD cannot be calculated as there was only one value</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intravenous- Hydrocortisone NA Succinate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300">SD cannot be calculated as there was only one value</measurement>
                    <measurement group_id="O2" value="500" spread="141.421"/>
                    <measurement group_id="O3" value="NA">no participants in this treatment group took this SCS</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intravenous- Methylprednisolone NA Succinate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="28.284"/>
                    <measurement group_id="O2" value="80">SD cannot be calculated as there was only one value</measurement>
                    <measurement group_id="O3" value="NA">no participants in this treatment group took this SCS</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral- Methylprednisolone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">no participants in this treatment group took this SCS</measurement>
                    <measurement group_id="O2" value="32">SD cannot be calculated as there was only one value</measurement>
                    <measurement group_id="O3" value="NA">no participants in this treatment group took this SCS</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral - Prednisolone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="42.426"/>
                    <measurement group_id="O2" value="90">SD cannot be calculated as there was only one value</measurement>
                    <measurement group_id="O3" value="37.50" spread="24.749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral - Prednisone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40">SD cannot be calculated as there was only one value</measurement>
                    <measurement group_id="O2" value="40" spread="0"/>
                    <measurement group_id="O3" value="100" spread="70.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral - Prednisone equivalent dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" spread="66.765"/>
                    <measurement group_id="O2" value="106.11" spread="104.055"/>
                    <measurement group_id="O3" value="58.61" spread="49.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Indacaterol Concentrations at Day 1 and Day 14</title>
        <description>Maximum plasma concentration after drug administration (Cmax) was measured for indacaterol acetate 75 µg and indacaterol acetate 150 µg for Pharmacokinetic (PK) Subgroup</description>
        <time_frame>Day 1 and Day 14</time_frame>
        <population>Pharmacokinetic (PK) profiling subgroup included all randomized patients who consented to participate in the additional PK assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol Acetate 75 µg</title>
            <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol Acetate 150 µg</title>
            <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Indacaterol Concentrations at Day 1 and Day 14</title>
          <description>Maximum plasma concentration after drug administration (Cmax) was measured for indacaterol acetate 75 µg and indacaterol acetate 150 µg for Pharmacokinetic (PK) Subgroup</description>
          <population>Pharmacokinetic (PK) profiling subgroup included all randomized patients who consented to participate in the additional PK assessment.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=21, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" spread="29.1"/>
                    <measurement group_id="O2" value="164" spread="69.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=21, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129" spread="48.6"/>
                    <measurement group_id="O2" value="285" spread="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Indacaterol Acetate 75 mcg</title>
          <description>indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
        </group>
        <group group_id="E2">
          <title>Indacaterol Acetate 150 mcg</title>
          <description>indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Disclosure Office</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+1(862)778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

